Hodgkin lymphoma residual disease and relapse detected by FDG-PET

11-15-2006

Residual disease and relapse of Hodgkin lymphoma (HL) could be detected by FDG-PET.

According to recent research from Sweden, "The aim of this retrospective study was to compare the value of FDG-PET with conventional imaging in patients with residual disease or suspected relapse in HL. We reviewed the records of all patients with HL who were referred for FDG-PET at our PET centre between April 2002 and August 2004."

"Thirty-four FDG-PET scans performed on 26 patients were included in the study. Referrals were based on either the presence of a residual mass on computed tomography (CT) (n=13) or suspicion of relapse (n=21). We found 1 false negative and 1 false positive FDG-PET scan," explained M. Bjurberg and colleagues, University of Lund Hospital.

The researchers concluded, "The high positive predictive value of FDG-PET in the residual group and the high negative predictive value in the relapse group strongly indicate that FDG-PET has an important role to play in the management of HL."

Bjurberg and colleagues published their study in Acta Oncologica (FDG-PET in the detection of residual disease and relapse in patients with Hodgkin's lymphoma. Experience from a Swedish centre. Acta Oncol, 2006;45(6):743-749).

For additional information, contact M. Bjurberg, University of Lund Hospital, Dept. of Oncology, S-22185 Lund, Sweden.

Publisher contact information for the journal Acta Oncologica is: Taylor & Francis AS, PO Box 12 Posthuset, NO-0051 Oslo, Norway.

Keywords: Lund, Sweden, Lymphoma, Oncology, Residual Disease, Relapse, Hodgkin Lymphoma, Diagnostics, Diagnosis, FDG-PET.

This article was prepared by Clinical Oncology Week editors from staff and other reports. Copyright 2006, Clinical Oncology Week via NewsRx.com.